Search Medical Condition
Please enter condition
Please choose location from dropdown

Montpellier cedex 05, France Clinical Trials

A listing of Montpellier cedex 05, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (398) clinical trials

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Phase

0.0 miles

Learn More »

Usefulness of Anticoagulant Treatment in First Isolated Symptomatic Calf Vein Thrombosis

This study will compare the evolution of the infrapopliteal DVT into two groups of patients, one treated with LMWH (Nadroparine) + elastic compression during 6 weeks and the second one treated with a placebo + elastic compression during 6 weeks. Patients will be assigned to intervention groups by chance, and ...

Phase

0.0 miles

Learn More »

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

OBJECTIVES: Primary - To determine the objective tumor response rate in patients with locally advanced or metastatic papillary renal cell carcinoma treated with sunitinib malate. Secondary - To evaluate the safety of this drug in these patients. - To determine time-to-event variables of overall survival, time to disease progression, time ...

Phase

0.0 miles

Learn More »

Radiation Therapy Chemotherapy and Cetuximab Followed by Surgery Chemotherapy and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery

OBJECTIVES: Primary - Determine the complete remission rate at 6 months after neoadjuvant radiotherapy, capecitabine, and oxaliplatin (XELOX), and cetuximab followed by surgery, adjuvant FOLFOX 4, and cetuximab in patients with synchronous locally advanced or metastatic cancer of the rectum with resectable metastases (T3-4 Nx or T2 N+ M1). Secondary ...

Phase

0.0 miles

Learn More »

Capecitabine Irinotecan and Oxaliplatin in Treating Patients With Metastatic Cancer

OBJECTIVES: Primary - Determine the maximum tolerated dose and dose-limiting toxicities of capecitabine. Secondary - Determine the recommended phase II dose of capecitabine. - Define the toxicity profile. - Evaluate potential antitumor activity in terms of objective response, duration of response, and time to disease progression. - Evaluate the pharmacokinetic ...

Phase

0.0 miles

Learn More »

Fluorouracil Cisplatin Cetuximab and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery

OBJECTIVES: Primary - To determine the maximum tolerated dose of fluorouracil and cisplatin when administered with cetuximab concurrently with esophageal radiotherapy. (Phase I) - To determine the complete histological response rate (after surgical resection). (Phase II) Secondary - To determine progression-free survival and overall survival. (Phase II) - To determine ...

Phase

0.0 miles

Learn More »

Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression

The aim of this study is to appreciate the relationship between: - extension of coronary calcifications and chronic renal failure progression - extension of coronary calcifications and levels of osteoprotegerin (bone disease marker) - cardiovascular risk factors and coronary calcifications - cardiovascular risk factors and existence of cardiovascular diseases

Phase N/A

0.0 miles

Learn More »

Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer

OBJECTIVES: Primary - Analyze various biological factors that can be used as markers to predict response to treatment and correlate with the signaling pathway of EGFR. Secondary - Establish a tissue bank to store information about the response to treatment and survival. OUTLINE: Patients undergo endoscopy, 11 biopsies of tumor ...

Phase N/A

0.0 miles

Learn More »

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

All Medtronic market-released leads and all market-released IPG, ICD and CRT devices are eligible to be included in this study.

Phase N/A

0.0 miles

Learn More »

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Phase

0.0 miles

Learn More »